What is the stepwise approach for managing asthma using inhalers, including the treatment ladder for inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA)?

Stepwise Asthma Inhaler Treatment Ladder

Quick-Relief Medication (All Steps)

All patients with asthma should have a short-acting beta-agonist (SABA) available for acute symptom relief, used as needed. 1 If you're using your SABA more than 2 days per week for symptom relief (not counting pre-exercise use), this signals inadequate control and indicates you need to step up to daily controller therapy. 1, 2

---

Step 1: Intermittent Asthma

For intermittent asthma (symptoms <2 days/week, nighttime awakenings <2x/month), use only as-needed SABA without daily controller medication. 1, 3

---

Step 2: Mild Persistent Asthma

When symptoms occur ≥2 days/week or SABA use exceeds 2 days/week, initiate daily low-dose inhaled corticosteroid (ICS) as the preferred controller therapy. 1, 2, 3

• Preferred: Low-dose ICS daily (200-250 mcg fluticasone propionate equivalent) plus as-needed SABA 2, 3, 4
• Alternative options: Leukotriene receptor antagonist (LTRA), cromolyn, or nedocromil if ICS cannot be tolerated 1, 3
• Critical action before prescribing: Verify proper inhaler technique, assess medication adherence, and address environmental triggers before assuming treatment failure 2, 3
• Patient instruction: Rinse mouth with water after each ICS dose without swallowing to prevent oral candidiasis 5

---

Step 3: Moderate Persistent Asthma

If asthma remains uncontrolled on low-dose ICS alone, the preferred approach is adding a long-acting beta-agonist (LABA) rather than increasing the ICS dose. 1, 6

• Preferred: Low-to-medium dose ICS + LABA combination inhaler (e.g., fluticasone/salmeterol or budesonide/formoterol) 1, 6
• Alternative: Medium-dose ICS alone, or low-to-medium dose ICS + LTRA 1
• Evidence basis: Adding LABA to ICS is more effective than doubling the ICS dose for achieving asthma control 1, 6, 7
• Critical safety warning: LABAs must NEVER be used as monotherapy—they carry an FDA black box warning for increased risk of asthma-related deaths when used without ICS 1, 6, 5
• Maximum LABA dosing: Do not exceed 100 mcg salmeterol or 24 mcg formoterol daily 1
• Before stepping up: First verify inhaler technique, medication adherence, and environmental control 1, 2

---

Step 4: Severe Persistent Asthma

For patients requiring step 4 care, use medium-dose ICS/LABA combination therapy, and consider consultation with an asthma specialist. 1

• Preferred: Medium-dose ICS + LABA 1
• Alternative: Medium-dose ICS + LTRA, theophylline, or zileuton 1
• Specialist consultation: Strongly consider at this step 1

---

Step 5: Severe Persistent Asthma with Additional Therapy

Use high-dose ICS/LABA combination, and consider adding omalizumab for patients ≥12 years with allergic asthma (elevated IgE, positive skin testing or RAST). 1

• Preferred: High-dose ICS + LABA 1
• Add-on for allergic asthma: Omalizumab (anti-IgE therapy) for patients with documented IgE-mediated disease 1
• Evidence: Omalizumab reduces exacerbations in patients with severe allergic asthma inadequately controlled on high-dose ICS 1

---

Step 6: Most Severe Persistent Asthma

For the most severe asthma, use high-dose ICS/LABA plus oral corticosteroids, with consideration of omalizumab for allergic asthma. 1

• Preferred: High-dose ICS + LABA + oral corticosteroid (typically 1-2 mg/kg/day, generally not exceeding 60 mg/day) 1
• Add-on for allergic asthma: Omalizumab 1
• Goal: Make repeated attempts to reduce systemic corticosteroids while maintaining control with high-dose ICS 1
• Before adding oral steroids: Consider trial of high-dose ICS/LABA + LTRA, theophylline, or zileuton, though this approach lacks clinical trial evidence 1

---

Key Monitoring and Adjustment Principles

Reassess asthma control every 2-6 weeks after initiating or changing therapy, evaluating symptom frequency, nighttime awakenings, SABA use, activity limitation, and lung function. 1, 2, 3

• Step up therapy when: SABA use exceeds 2 days/week for symptom relief, symptoms worsen, or exacerbations occur 1, 2
• Step down therapy when: Asthma is well-controlled for at least 3 consecutive months 1
• Stepping down from ICS/LABA: Reducing to a lower dose of ICS/LABA combination (e.g., from 250/50 to 100/50 mcg) is more effective than switching to ICS alone at maintaining control 7
• Before stepping up: Always first verify proper inhaler technique, medication adherence, and environmental control 1, 2

---

Critical Safety Considerations

LABAs carry an FDA black box warning and must only be prescribed in fixed-dose combination with ICS, never as monotherapy. 1, 6, 5

• Patient education: Patients must understand that ICS/LABA inhalers are for maintenance therapy only, not acute symptom relief—use SABA for acute symptoms 6, 5
• Do not use additional LABA: Patients on ICS/LABA should not use additional LABA for any reason 5
• Oral candidiasis prevention: Instruct patients to rinse mouth after ICS use 5

---

Allergen Immunotherapy Consideration

For patients at steps 2-4 with allergic asthma (especially children), consider subcutaneous allergen immunotherapy as adjunctive therapy. 1

• Evidence strongest for: Single allergen immunotherapy targeting house dust mites, animal danders, and pollens 1
• Clinician requirement: Must be prepared and equipped to identify and treat anaphylaxis 1